Connect Biopharma (NASDAQ:CNTB) Posts Earnings Results, Beats Expectations By $0.01 EPS

Connect Biopharma (NASDAQ:CNTB – Get Free Report) announced its earnings results on Monday. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.01, Zacks reports.

Connect Biopharma Stock Performance

Shares of NASDAQ CNTB traded down $0.03 during mid-day trading on Monday, reaching $0.64. 475,502 shares of the company were exchanged, compared to its average volume of 1,360,423. The stock has a market capitalization of $40.49 million, a P/E ratio of -0.54 and a beta of 0.06. The company has a quick ratio of 2.37, a current ratio of 2.37 and a debt-to-equity ratio of 0.01. The company’s 50-day simple moving average is $1.04 and its 200-day simple moving average is $2.11. Connect Biopharma has a twelve month low of $0.60 and a twelve month high of $3.82.

Analyst Upgrades and Downgrades

Several research firms have recently commented on CNTB. Leerink Partners began coverage on Connect Biopharma in a report on Monday, October 12th. They issued an “outperform” rating and a $4.00 price objective for the company. BTIG Research lowered their target price on shares of Connect Biopharma to $5.00 and set a “buy” rating on the stock in a report on Wednesday, September 30th. Canaccord Genuity Group dropped their price target on shares of Connect Biopharma from $7.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, September 16th. Wall Street Zen cut shares of Connect Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, October 31st. Finally, Weiss Ratings downgraded shares of Connect Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, October 21st. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $5.88.

Read Our Latest Stock Analysis on CNTB

Connect Biopharma Company Profile

(Get Free Report)

Connect Biopharma is a biopharmaceutical company focused on developing treatments for inflammatory diseases, particularly conditions driven by T cells. The company has operated in the United States and China and has advanced its drug candidates through clinical development. Its lead candidate, rademikibart (formerly CBP-201), is an investigational antibody that targets the interleukin-4 receptor alpha pathway, which is involved in allergic inflammation. It has been studied for conditions including atopic dermatitis and asthma.

See Also

Earnings History for Connect Biopharma (NASDAQ:CNTB)

Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.